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Background: Although recent progress has been made in treating castration resistant prostate cancer, the interplay of
signaling pathways which enable castration resistant growth is incompletely understood. A data driven, multivariate
approach, was used in this study to predict prostate cancer cell survival based on the phosphorylation levels of key
proteins in PC3, LNCaP, and MDA-PCa-2b cell lines in response to EGF, IGF1, IL6, TNFα, dihydrotestosterone, and
docetaxel treatment.
Methods: The prostate cancer cell lines were treated with ligands or inhibitors, cell lyates were collected, and the
amount of phosphoprotein quantified using 384 well ELISA assays. In separate experiments, relative cell viability was
determined using an MTT assay. Normalized data was imported into Matlab where regression analysis was performed.
Results: Based on a linear model developed using partial least squares regression, p-Erk1/2 was found to correlate with
castration resistant survival along with p-RPS6, and this model was determined to have a leave-one-out cross validated
R2 value of 0.61. The effect of androgen on the phosphoproteome was examined, and increases in PI3K related phos-
phoproteins (p-Akt, p-RPS6, and p-GSK3) were observed which accounted for the majority of the significant increase in
androgen-mediated cell survival. Simultaneous inhibition of the PI3K pathway and treatment with androgen resulted in
a non-significant increase in survival. Given the strong effect of PI3K related signaling in enabling castration resistant
survival, the specific effect of mTor versus complete inhibition was examined using targeted inhibitors. It was determine
that mTor inhibition accounts for 52% of the effect of complete PI3K inhibition on cell survival. The differences in
signaling between the cell lines were explored it was observed that MDA-PCa-2b exhibited far less activation of
p-Erk in response to varying treatments, explaining one of the reasons for the lack of castration resistance.
Conclusion: In this work, regression analysis to the phosphoproteome was used to illustrate the sources of castration
resistance between the cell lines including reduced p-Erk signaling in MDA-PCa-2b and variations in p-JNK across the
cell lines, as well as studying the signaling pathways which androgen acts through, and determining the response to
treatment with targeted inhibitors.
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Every year 223,000 men will be diagnosed with prostate
cancer in the United States with most patients having
androgen dependent disease at the initial stages [1].
Although there have been recent advances in treating
castration resistant prostate cancer, prognoses are still
poor once the disease progresses to the castration resistant,* Correspondence: david.kaplan@tufts.edu
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anisms reported which can enable castration resistant
growth including intracrine synthesis of androgen, upreg-
ulation of the androgen receptor (AR), co-activation of the
AR by other pathways, or complete bypass of androgen
signaling through the activation of other pathways [4-6].
These mechanisms can include activation of oncogenes,
mutation of tumor suppressors, epigenetic alterations,
or activation of a pathway through extracellular matrix or
ligand cues contained in the microenvironment.ed Central Ltd. This is an Open Access article distributed under the terms of the
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resistant growth have been studied using various cell
line models, including PC3, LNCaP, and MDA-PCa-2b
cells lines. These cell lines display a range of phenotypes,
including aggressive castration resistant growth in PC3
cells and androgen-dependent growth in LNCaP and
MDA-PCa-2b cells. These cell lines additionally display
various mutations in their genome with LNCaP and PC3
cells having inactivated PTEN (Phosphatase and tensin
homolog) and MDA-PCa-2b cells having intact PTEN
[7,8].These differences are used to model the variation
present in patients with differing stages of disease pro-
gression. Depending on the cell line, certain growth
factor treatments such as EGF (Epidermal growth factor)
or IGF1 (Insulin-like growth factor 1), or targeted kinase
inhibitor treatments, can enhance castration resistant
growth or treat castration resistant cancer through modu-
lating signal transduction pathways.
The analysis of prostate cancer signaling often involves
the examination of numerous pathways through genomics,
transcriptomics, or proteomics. The relationship of these
data sets to cell phenotype is often multivariate and non-
intuitive. To investigate these relationships, multivariate
linear regression techniques have been utilized over the
last decade, and have been successful in correlating the
signaling of multiple pathways using phosphoproteomic
data to phenotypic outcomes including apoptosis, prolifer-
ation, invasion, and migration [9-11]. Partial least squares
(PLS) regression is a multiple linear regression algorithm
which correlates variation in the Y matrix (cell survival)
to the X matrix (phosphoprotein levels) by identifying
vectors which simultaneously describe variation in both
data sets. These latent variables are able to account for
the multicollinearity of similarly regulated phosphopro-
teins (i.e. phosphosites which may be part of the same
pathway or crosstalk between pathways).
In the present work, the objective was to correlate
castration resistant growth to pathway activation via
phosphoproteomic signaling using regression analysis.
The use of the PC3, LNCaP, and MDA-PCa-2b cell lines
allowed us to capture diversity in different prostate cancer
genotypes, and make comparisons across cell lines. The
epigenetic and genetic variations are assumed to be
abstracted into the levels of phosphoprotein activation
(i.e., PTEN inactivating mutations causing higher levels
of p-Akt) with differences in unmeasured pathways
across cell lines being sources of error in the model.
This approach enables the exploration of a range of hy-
potheses to understand how cell signaling drives cas-
tration resistance, the importance of various signaling
proteins in enabling castration resistant growth, the
correlation between these signaling proteins, and the
specific effect of various targeted kinase inhibitors in
modulating the effect of these signaling proteins. Thiswork will aid in the long term goal of optimizing the
inhibition of signaling pathways to prevent castration
resistant prostate cancer progression.
Methods
Cell culture and reagents
LNCaP, MDA-PCa-2b, and PC3 cell lines were acquired
from ATCC (Manassas, VA, USA). PC3 and LNCaP cells
lines were cultured in 10% fetal bovine serum (FBS), RPMI
1640, and 1% antibiotic-antimycotic. The MDA-PCa-2b
cell line was cultured in BRFF-HPC1 media purchased
from AthenaES (Baltimore, MD, USA) supplemented with
20% FBS. Dihydrotestosterone was acquired from Sigma-
Aldrich (St. Louis, MO, USA). Androgen depleted media
consisted of 10% charcoal stripped FBS with phenol red
free RPMI 1640. Docetaxel was acquired from Sigma-
Aldrich. Temsirolimus and SB202190 were purchased
from Selleckchem (Houston, TX, USA). All other inhibi-
tors were purchased from EMD Millipore (Billerica,
MA, USA). Unless otherwise stated all other cell culture
reagents were acquired from Invitrogen (Grand Island,
NY, USA).
Cell survival assay
Relative cell viability was assessed using an MTT ((3-
(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
assay acquired from Invitrogen. As previously determined
by our lab, MTT correlates to relative cell number as con-
firmed via DNA quantification and manual cell counting
[12]. All three cell lines were plated at a concentration of
5,000 cells/cm2 in a 24 well plate in their respective
growth media. The cells were allowed to adhere for
24 hours. The media was then changed to androgen
depleted media which the cells were cultured in for an
additional 72 hours. Finally, relative cell viability was
determined using an MTT assay according to the manu-
facturer’s instructions. Targeted kinase inhibitors were
used at the following concentrations: LY294002 at 7 μm,
U0126 at 325 nm, Wedelolactone at 10 μm, Temsirolimus
at 50 nm, and SB202190 at 500 nm. Additionally, the total
protein amount of biological replicates from each cell type
was measured using a Bicinchoninic assay purchased from
Thermo Scientific (Rockford, IL, USA). After measuring
cell survival with an MTT assay the results were normal-
ized to total protein measured to account for variations in
cell size between the cell lines.
Measuring phosphoprotein levels
Each prostate cancer cell line was plated to six well
plates at a density of 7,500 cells/cm2 in their respective
growth media and allowed to adhere for 24 hours. After
24 hours cells were treated with androgen depleted media
supplemented with the appropriate treatment. For studies
involving the use of inhibitors on LNCaP cells, the cells
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before additional treatments were added to ensure
complete inhibition. Following the appropriate amount
of time (30 minutes, 4 hours, or 24 hours) the media
was removed and the cells were lysed. R&D Systems
(Minneapolis, MN, USA) Duoset ELISA kits were used
to quantify the amount of phosphoprotein present in
each sample. Lysates were processed and the assays
performed according to manufacturer’s instructions. A
Bicinchoninic acid assay was performed on each lysate
and the lysates were diluted such that 20 ug of protein
lysate was used in each ELISA assay. The lysis buffer
was made by combining 20 ml of PBS, 1nM of EDTA,
5 mM NaF, 6 M Urea, 0.1 ml of Triton ×100, and 2
packets on Halt protease/phosphatase inhibitors from
Thermo Scientific (Waltham, MA, USA). Briefly, the
antibody pairs for the ELISA assays were optimized on
384 well ELISA plates from Santa Cruz Biotechnology
(Dallas, Texas, USA) using the accompanied positive
control samples. An eight point standard curve was gener-
ated and fitted using a second order polynomial. The
amount of phosphoprotein in ng per 20 ug of total protein
lysate was then determined by comparing the measured
absorbance of the sample to the standard curve.
Data analysis
Following data acquisition, calibration to the ELISA stand-
ard curve, and normalization to total protein content, the
data was imported into Matlab (The Mathworks, Natick,
MA) where both protein (X matrix) and survival data
(Y matrix) were mean centered and unit variance
scaled. The data was arranged such that each column
of the X matrix represented a phosphoprotein at a specific
time (8 phosphoproteins × 3 time points = 24 columns).
The rows represent the cell treatments with the values in
the X matrix corresponding to phosphorylation levels and
the rows of the Y matrix corresponding to relative cell sur-
vival in response to that treatment. The X and Y matrices
were then inputted into a function which utilizes the
native plsregress function packaged with Matlab to
employ the SIMPLS algorithm and calculate the regression
coefficients. This was repeated with each row (treatment
condition) left out. The calculated model was applied
to the left out data to determine a predicted Y value.
The R2 value was then calculated using the measured
(Y vector) and predicted survival data. Partial least
squares regression is a multiple regression algorithm
which attempts to explain the Y matrix by finding a
multidimensional direction in the X space which explains
the maximum variation in both matrices [10]. This algo-
rithm is especially suited to applications where the X matrix
contains many more variables than observations, or when
many of the X variables are multicollinear, as is often the
case in cell signaling data.An approach for calculating significance in PLS regres-
sion models was employed which randomizes the X matrix
(phosphoprotein data) as compared to the Y matrix
(survival data) and performs regression analysis. From
this randomized regression a R2 is calculated and saved.
We repeated this procedure 3,000 times and determined a
mean R2 and standard deviation for these calculated ran-
dom models. The randomized R2 values were assumed to
follow a normal distribution. Using the mean and standard
deviation from the R2 values calculated for randomized
regression, and the R2 of the correctly calculated model,
the number of standard deviations away from the random
mean was determined (z-score), and from this a p-value
determined.
The level of phosphoprotein activation in response to
ligand treatment was calculated as a percent increase
over untreated controls. This data was imported into
Cytoscape and used as relative measures of edge thick-
ness between ligand and the resulting phosphoproteins
[13]. Decreases in phosphoprotein levels in response to
treatment were depicted as a red edge.
Correlation modeling
To model the correlation between the phosphosites in
the three different cell lines, the Pearson correlation
between all possible unique pairs of phosphosites within
the same cell line were assessed and a P-value calculated
which represents the statistical significance of the correl-
ation. This was completed on observations for untreated
cells, EGF, IGF1, IL6, TNFα, DHT, and docetaxel treated
cells using all three time points (30 minutes, 4 hours,
and 24 hours). The Q-value (P-value equivalent adjusted
for multiple hypothesis testing) was also determined
using the Q-value software downloaded from the Storey
lab website to adjust for multiple hypothesis testing [14].
Results
Measuring phosphorylation and castration resistant
survival in response to treatment
To obtain a diverse response across multiple phosphosites
in LNCaP, PC3, and MDA-PCa-2b cells, the cells were
treated with the ligands EGF (Epidermal growth factor),
IGF1 (insulin-like growth factor 1), IL6, TNFα (Tumor
necrosis factor alpha), dihydrotestosterone (DHT) which
is an androgen receptor agonist, and the chemotherapeu-
tic docetaxel. LNCaP cells were additionally treated with
the targeted kinase inhibitors LY294002 (Phosphoinositide
3-kinase (PI3K) inhibitor), U0126 (Mitogen-activated
protein kinase kinase (MEK) inhibitor), wedelactone
(IκB Kinase (IKK) α/β inhibitor), temsirolimus (Mammalian
target of rapamycin (mTOR) inhibitor), and SB202190 (p38
inhibitor), each in combination with the previously men-
tioned ligands (Additional file 1: Table S4). These ligands
and drugs were selected because of their involvement in
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implicated in castration resistant growth of prostate cancer,
as well as their availability and characterized activity. Whole
cell lysates were collected at 30 minutes, 4 hours, and
24 hours post treatment and assayed using 384 well plate
phospho-ELISA assays to measure the response of phos-
phorylation sites in key pathways to treatment with these
ligands and inhibitors. In the signaling pathways diagram,
a simplistic representation of the interactions between the
measured phosphoproteins, the pathways which contain
those proteins, and the effect of the targeted inhibitors
can be observed (Figure 1A). The phosphosites which
were measured in response to treatment are listed (see
Phosphosites measured). These particular phosphosites
were selected based on an examination of the literature,
















After the phosphoprotein data was collected and nor-
malized (see methods), hierarchical clustering analysis
was applied across the phosphosites at the three timeFigure 1 An overview of the measured signaling pathways and respon
signaling between the phosphoproteins measured (blue lettering), the treatm
LNCaP cells (red lines). B) Heatmap with hierarchical clustering illustrating the
values in response to varying treatments (see Methods), as well as survival valpoints as well as the treatment groups. This analysis
measures the similarity between each observation using
a Euclidean distance metric (Figure 1B). Across the y
dimension of the X matrix, the treatments were found
to cluster first by cell line and then by inhibitor treat-
ment (for LNCaP cells only), with little clustering in the
ligand treatment groups (Figure 1B and Additional file 2:
Table S1). In the x dimension the phosphoprotein activa-
tion was generally found to cluster the three time points of
each phosphoprotein together (Figure 1B and Additional
file 3: Table S2). This clustering indicated that the cell line,
and then inhibitor, and finally the ligand treatment
imparted the most substantial changes in the cells in the
y dimension (treatment conditions). In the × dimension
(phosphoproteins), the data indicated that the change
by time point tended to cause the most substantial re-
sponse in phosphoprotein levels.
For each treatment, biological duplicates were measured
and the absolute percentage difference between the two
replicates was determined (Additional file 4: Table S3). A
mean difference of 20.4% was observed across all cell lines
which when compared to the finding that the phospho-
sites varied by approximately 670% on average over un-
treated controls, was considered an acceptable amount
of error.
Regression analysis correlating phosphoprotein
measurements to cell survival in androgen depleted
conditions
In an attempt to understand how the alterations in signal-
ing may lead to variations in survival outcomes in cells
grown in androgen depleted conditions, we built a statis-
tical model using PLS regression. The data was arranged
so that the phosphoprotein data was regressed against the
survival data using PLS regression on the complete data
set of 8 phosphoproteins, at 3 time points, using 3 cellses to treatment. A) A diagrammatic overview illustrating the cell
ents used (green lettering), and the inhibitors which were used on the
mean centered and variance scaled (z-score) changes in phosphoprotein
ues of LNCaP, PC3, or MDA-PCa-2b cells as measured via a MTT assay.
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parameters the leave-one-out cross validated R2 value
was determined to be 0.616 with 3 latent variables, and
the predicted versus measured survival values were
plotted (Figure 2A). Additional latent variables beyond
three had marginal explanatory power due to the fact
that the majority of the variation in the X matrix could
be described in terms of these latent variables, therefore
three components were used for all analyses. When this
calculated R2 value was compared to the mean R2 value
calculated from randomized models (X matrix rows
randomized against Y matrix rows) we observed that
this model was 6.36 standard deviations above the
mean randomized value of 0.1847 corresponding to a
P-value less than 0.0001. This result indicates that this
model can correlate to survival significantly better than
by random chance.
Upon determining that this model was significantly
more accurate than a randomized model, we examined
the regression coefficients to determine weights calculatedFigure 2 Partial least squares regression results with three principal com
values for each different treatment group across all three cell lines (LNCaP, PC
across the 3 time points. C) The mean absolute value of the regression coeffic
model. D) The R-squared value as additional phosphoproteins are added to a
R-squared value of Erk is for a model built on Erk data alone. The R-squared v
value for p38 is for the complete model for all data and is 0.577.on the different phosphoproteins. Consistently positive
coefficients for p-Erk (Extracellular signal-regulated
kinases) were noted, as well as consistently increased
p-RPS6 (Ribosomal protein S6) across all time points
(Figure 2B). p-JNK regression coefficients were negative at
all time points along with p-Akt and p-Stat3. p-GSK3
(Glycogen synthase kinase 3) additionally had minimal
early and late time point regression coefficients, how-
ever had a substantially increased 4 hour regression
coefficient.
In order to better assess the contribution of the regres-
sion coefficients to the model outcome the absolute value
of the coefficients was taken for each time point and the
mean plotted for each phosphoprotein in descending
order (Figure 2C). From this, p-Erk was determined
to most strongly contribute to the model, followed by
p-RPS6 and p-JNK. We used this data to plot the R2
value of models built on increasing amounts of data,
starting with p-Erk and adding phosphoproteins in order
of their mean absolute value of regression coefficients. Itponents. A) A scatter plot illustrating the measured versus predicted
3, MDA-PCa-2b). B) The regression coefficients for all 8 phosphoproteins
ients, indicating the contribution of that phosphoprotein to the overall
3 principal component partial least squares regression model. The
alue for RPS6 is for a model built on Erk and RPS6 data. The R-squared
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and p-JNK resulted in R2 values of 0.4655 as compared to
the complete model which gave us a R2 value of 0.616
(Figure 2D). Beyond these phosphoproteins, only the Akt
phosphoprotein added substantial further information to
the model, increasing the R2 from 0.484 to 0.570, indicat-
ing this data added substantial accuracy to the model
without having a large regression coefficient. From these
results it was concluded that the phosphorylation levels of
Erk, RPS6, JNK, and Akt were able to explain the majority
of variation in castration resistant survival across these
three cell lines.
The amount of error between the predicted values from
the model and the measured values were also grouped by
treatment, cell line, and inhibitor (for LNCaP cells treated
in combination with targeted inhibitors) (Additional file 5:
Figure S1A, B, and C). The only significant difference that
was observed between any conditions was a much higher
docetaxel error (Additional file 5: Figure S1A). This is
likely due to the fact that docetaxel is a chemotherapeutic
which causes cell death, however little variation in the
phosphoproteome as compared to controls was seen.
Therefore a model of phosphoproteomic signaling was
unable to predict docetaxel’s apoptotic effect.
The effect of androgen treatment on phosphoprotein
signaling
The effect of DHT on phosphoprotein activation was
examined across the different treatments conditions.
Previous research indicates that the activated AR may
act through growth factor pathways such as PI3K (Phos-
phoinositide 3-kinase), and by causing the transcription
of genes which may directly activate the cell cycle [22].
Upon examining the DHT treatment group an increase
in the 24 hour p-RPS6 and p-Akt levels as compared to
controls was observed in LNCaP cells (Figure 3A). The
effect of DHT on PC3 and MDA-PCa-2b cells was also
examined. PC3 cells exhibited no substantial alterations
in signaling which is consistent with previous reports
where PC3 cells had minimal to no AR expression [23].
MDA-PCa-2b cells exhibited an increase in p-RPS6 and
p-GSK3β at 4 hours which was not maintained through
24 hours, although DHT treatment of MDA-PCa-2b
cells did not cause survival increases to the extent that
EGF or IGF1 treatment did.
The survival of LNCaP cells in response to DHT treat-
ment was examined and an increase of 38% was observed
as compared to the control condition (Figure 3B). This
survival advantage was completely abrogated when treated
in combination with LY294002 (PI3Ki) which reduced
p-Akt, p-GSk3, and p-RPS6 to below baseline levels at
all time points. The combination of DHT plus LY294002
caused a non-significant increase in survival of 25% over
the treatment of LY294002. There was little difference inphosphoprotein levels from LY294002 treatment alone,
indicating direct activation of the cell cycle by AR or
activation of other non-measured pathways by AR other
than PI3K.
Based on these observations we propose a modification
of the model originally proposed by Gosh et al. (Figure 3C)
[24]. Here, the PI3K pathway can activate the AR which
can activate the cell cycle. However, activation of the AR
can also activate the PI3K pathway. Additionally, activa-
tion of the PI3K pathway can activate cell cycle through
bypassing the AR via mTOR/RPS6.
Comparison of phosphoprotein alterations between
LNCaP, MDA-PCa-2b, and PC3 cell lines
The differences between the signaling of the three different
cell lines used were examined by taking the mean phospho-
protein level across all treatments, with the exception of
inhibitor treatments in LNCaP cells. Several observations
were noted in this data including the consistent trend
across p-Akt, p-RPS6, and p-GSK3 of higher values in the
LNCaP cells, somewhat reduced values in the PC3 cells,
and the lowest amount of phosphoprotein in MDA-PCa-
2b cells (Figure 4A). These phosphosites are part of the
PI3K pathway which likely explains their similar levels
of activation (the measured GSK3 phosphosites of
GSK3α at S21 and GSK3β at S9 are activated by p-Akt).
When p-Erk levels were measured in MDA-PCa-2b
cells, consistently lower amounts of this phosphoprotein
were found as compared to LNCaP and PC3 cells (10.7%
of LNCaP levels and 11.3% of PC3 levels, Figure 4A).
Based on the substantial weight placed on the p-Erk re-
gression coefficient, this explains one of the major reasons
for reduced castration resistance in MDA-PCa-2b cells.
A final observation made regarding the mean phospho-
protein levels across all treatments was the decreasing
levels of phosphorylation in JNK from MDA-PCa-2b cells
to LNCaPs and then PC3 cells (Figure 4B, C, and D). Ini-
tially, this was a counterintuitive observation due to the
fact that this phosphosite has previously been described as
an oncogene, and we have measured castration resistance
in the cell lines inverse to the amount of p-JNK (Additional
file 6: Figure S2) [25]. However, this observation corrobo-
rates recent work indicating that JNK acts as an oncogene
in tumor development and a tumor suppressor in regards
to castration resistant growth [19].
In order to better illustrate the activation of phosphopro-
teins between cell lines in response to treatments, graphs
were created which plot the phosphoprotein response as a
function of edge thickness (Figure 5A, B, and C). Upon
examining these graphs substantial variation between the
cell lines is observed with the most castration resistant cell
line, PC3, having the weakest response generally to the
various treatments, followed by moderate responses in
LNCaP cells, and strong sensitivity to certain growth
Figure 3 Modeling the effect of androgen treatment of cell signaling. A) The percent change in phosphoprotein levels due to DHT
treatment of LNCaP cells in androgen depleted media as compared to the control condition. A HSP27 phosphorylation value of 3200% was
observed at the 30 minute time point. B) The relative survival of LNCaP cells under various treatment conditions in response to androgen
treatment (DHT), a PI3K inhibitor (LY294002), or a combination of DHT and LY294002 in androgen depleted media as compared to the control
condition of androgen depleted media. DHT is significantly greater than all other groups (** equals P-value < 0.01). Error bars are std. dev. from
mean. Values are normalized to the untreated control condition’s mean. C) A diagrammatic overview of the proposed signaling interactions
between the androgen receptor, PI3K signaling pathway, RPS6, and cell cycle targets.
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differences between the cell lines in response to the
same growth factor. In PC3 and LNCaP cells EGF stimu-
lates Erk to various extents, however in MDA-PCa-2b
cells EGF had little effect on Erk and strongly increased
p-RPS6 along with IGF1 which was not seen to have an
effect LNCaP or PC3 cells.
Modeling the effect of treatments and targeted inhibitors
The effect of treatment with five targeted kinase inhibitors
on protein phosphorylation and the LNCaP cell survival
in androgen depleted media as compared to controls can
be seen (Figure 6A, B, and C). Cells were treated with con-
centrations five times the published IC50 (half maximal
inhibitory concentration) values of the target kinases
which, assuming a hill coefficient of one, is equal to IC83.
Some of the targeted kinase inhibitors did not reduce theirtarget phosphoproteins to the anticipated levels, possibly
due to degradation. Incomplete inhibition of targets
should have no effect on model performance because
the response is predicted according to actual measured
phosphoprotein levels. We calculated a separate PLS
regression model solely on all of the LNCaP data, includ-
ing inhibitor treatments. A leave-one-out cross valuidated
R2 value of 0.58 (Additional file 7: Figure S3) was observed
across this data set indicating that the response from in-
hibitor treatment can predict the majority of the variation
in cell survival.
The effect of complete PI3K inhibition with LY294002
versus mTor inhibition alone with temsirolimus was also
examined. Based on the relative survival levels of LNCaP
cells treated with LY294002 versus temsirolimus it was
determined that the temsirolimus treated group had 31%
increased cell survival over cells treated with LY294002.
Figure 4 The mean phosphorylation value for each phosphoprotein across the three cell lines. A) These phosphoprotein levels were
averaged from the EGF, IGF, IL6, TNFα, DHT, and docetaxel treatment in androgen depleted media for each cell line. B) JNK phosphorylation
values at 30 minutes for all three cell lines. C) JNK phosphorylation values at 4 hours for all three cell lines. D) JNK phosphorylation values
at 24 hours for all three cell lines. In B, C, and D all groups are significantly different from each other (* equals P-value < 0.05, ** equals
P-value < 0.01, and *** equals P-value < 0.001).
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levels which were near complete inhibition from basal
levels, while LY294002 also strongly reduced measured
p-Akt and p-GSK3 levels (Figure 6D and 6E). Based on
this observation it was concluded that signaling up-
stream of mTor (such as p-GSK3 which was observed to
be highly correlated to p-Akt) accounted for the differ-
ence in survival between complete PI3K inhibition and
inhibition of mTor alone.
Modeling the correlation between phosphosites’ activation
In order to better understand the correlation between
different phosphoproteins’ activation under the same
treatment we examined the Pearson correlation between
them across the three separate cell lines (for LNCaP cells
the inhibitor plus treatment data was excluded). The
most consistent theme across the cell lines was the positive
correlation between p-RPS6 and p-Akt, which occurs
through mTor (Q-value of 0.0531, 0.0391, and 0.0160, for
PC3, LNCaP, andMDA-PCa-2b cells, respectively, Figure 7).Additionally, there was a correlation between p-Akt and
p-GSK3 present in LNCaP cells (Q-value of 0.00569) and
MDA-PCa-2b cells (Q-value of 0.000216), but not PC3
cells (Q-value of 0.42972).
Discussion
The goal of this work was to examine how variation in
disparate signaling pathways altered castration resistant
growth of three different prostate cancer cell lines in
response to activating treatments and targeted inhibitors.
In future work, an understanding of how multiple sig-
naling pathways enable castration resistance in patients
will be critical to optimizing patient specific treatments
using targeted therapies. Differences in the basal level of
castration resistant growth across the three cell lines
were observed, as was their response to the treatments. A
regression model was developed for predicting castration
resistant growth and survival, using an MTT assay, which
far exceeded randomized data sets (P-value < 0.0001), and
was able to account for over half of the variation in cell
Figure 5 The relative activation of each phosphoprotein induced by each ligand treatment. Line thickness is proportional to percent
increase over untreated control of cells in androgen depleted media. Red lines indicate a reduction in phosphoprotein levels. A) The activation of
phosphoproteins in PC3 cells in response to ligand treatment. Red lines indicate a reduction in phosphoprotein levels. B) The activation of
phosphoproteins in MDA-PCa-2b cells in response to ligand treatment. C) The activation of phosphoproteins in LNCaP cells in response to
ligand treatment.
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mate metric of cell survival and abstracted the prolifera-
tion and apoptosis balance as well as other cellular
processes such as neuroendocrine differentiation into one
value representing total cell survival in androgen depleted
conditions in response to treatment. There are numerous
other pathways which are perturbed in prostate cancer by
the treatments used here, as well as epigenetic and genetic
variability which likely account for the remaining un-
explained variance in cell survival, however a majority of
cell survival can be explained by these 8 phosphoproteins’
activation level at three time points.
When the effect of androgen treatment on phosphopro-
teomic signaling was examined we observed an increase
in PI3K related phosphoprotein activation (p-Akt, p-RPS6,
p-GSK3) at later time points. This is consistent with the
observation that AR activation can cause activation of the
PI3K pathway, at least in part, through induction of IGF1secretion [6]. Previous work has indicated that activation
of the PI3K pathway can coactivate the AR, causing recip-
rocal feedback [26]. Additionally, the AR can cause the
transcription of cell cycle-related genes directly through
binding to the promoter elements and transcribing genes
such as c-Myc [27].
Phosphoprotein levels across cell lines were also exam-
ined and there was a clear inverse trend between innate
castration resistance and p-JNK levels which did not
substantially vary in response to treatment. As previously
discussed, this effect may play a role in castration resist-
ance [19]. This variation between cell lines was also seen
in the lack of consistent correlation between phosphosites
indicating that the genetic and epigenetic differences
between the cell lines significantly alters how cell signaling
networks respond to treatment. PI3K-related signaling was
the only exception to this which had somewhat conserved
correlation values across cell lines.
Figure 6 Response of LNCaP cells to targeted inhibitors. A) The relative cell survival of LNCaPs treated with targeted inhibitors in androgen
depleted media after 72 hours. Relative survival was normalized to untreated control LNCaPs in androgen depleted media (100%). Error bars are
std. dev. from mean. B) The degree to which each targeted inhibitor reduced phosphorylation of the phosphoprotein as compare to control
conditions. A thicker line indicates a stronger reduction in phosphorylation. Edges in average effect over 30 minutes, 4 hours, and 24 hours.
C) The degree to which each targeted inhibitor activated phosphorylation of the phosphoprotein as compare to control conditions. A thicker line
indicates an increase phosphorylation. Edges in average effect over 30 minutes, 4 hours, and 24 hours. D) The effect of LY294002 treatment on
p-Akt, p-GSK3, and p-RPS6. PI3K and mTor were not measured. A stronger color red indicates increased inhibition. E) The effect of Temsirolimus
treatment on p-Akt, p-GSK3, and p-RPS6. PI3K and mTor were not measured. A stronger color red indicates increased inhibition.
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http://www.biomedcentral.com/1471-2407/14/325To make additional comparisons PLS regression was
performed on the individual cell line data yielding
models of cell survival with high R-squared values
(LNCaP: R2 = 0.986, PC3: R2 = 0.998, and MDA-PCa-2b:
R2 = 0.969). Upon examining the regression coefficientsFigure 7 The correlation values between phosphoproteins across the
while red lines indicate a negative correlation. Solid lines indicate statistica
dotted lines indicate a P-value of less than 0.05 before multiple hypothesisfrom these models PC3 cells generally weighted positively
p-Erk, p-Stat3, p-RPS6, and p-GSK3 as compared to
LNCaP which generally weighted p-Erk, p-Stat3, and
p-GSK3 positively. Finally, MDA-PCa-2b weighted posi-
tively p-Akt, p-RPS6, and p-GSK3 in determining cellthree different cell lines. Black lines indicate a positive correlation
l significance when adjusted for multiple hypothesis testing while
correction.
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http://www.biomedcentral.com/1471-2407/14/325survival (Additional file 8: Figure S4). From this data it
can be seen that survival appears to be largely mediated
through PI3K-related signaling in MDA-PCa-2b cells with
an increasing role of p-Erk and p-Stat3 in LNCaP and
PC3 cells. Additionally, given the few preserved correla-
tions observed across all cell lines, the data indicates that
variations between cell lines cause substantial changes in
signaling crosstalk.
The use of targeted kinase inhibitors allowed the eluci-
dation of the role of particular phosphoproteins. Specific-
ally, we identified the role of phosphoproteins upstream of
mTor in the PI3K in enabling survival. In a recent phase
II clinical trial Temsirolimus as a single agent had an
effect on 32% of patients, and numerous PI3K inhibitors
are being investigated for use in prostate cancer [28].
Additionally, an increase in p-Erk was noted in response
to treatment with the p38 inhibitor SB202190 which is
consistent with the observation that p38 inhibition can
increase survival [29,30].
Conclusion
In this work, regression analysis was used to determine
how cell signaling correlates with castration resistant
growth across three cell lines. Based on the data presented,
in vitro prostate cancer cell androgen independent growth
could be largely described via MAPK (Mitogen-activated
protein kinases) and PI3K signaling. Androgen mediated
signaling also largely acted through PI3K signaling. p-JNK
appeared to potentially play a role in the fundamental cas-
tration resistance of a cell line, and MDA-PCa-2b cells did
not utilize p-Erk to enable androgen-independent growth.
Given the myriad of targeted inhibitors currently in devel-
opment, approaches similar to this work which determine
drivers of disease progression may enable optimizing
treatment given the unique signaling of each patient.
Additional files
Additional file 1: Table S4. Phosphoprotein and survival data for all
cell lines under ligand and inhibitor treatment. Phosphoprotein values
are the average of two biological replicates and are expressed as ng per
20 ug of protein lysate. Survival values are normalized measurements of
cell survival based on an MTT assay as described in the methods.
Additional file 2: Table S1. Mean percent error between duplicate
phosphoprotein measurements.
Additional file 3: Table S2. Row labels for the hierarchical clustering
heat map. Row names are in the order as they are presented on the heat
map in Figure 1B with the first row name representing the top row in
the heat map.
Additional file 4: Table S3. Column labels for the hierarchical
clustering heat map. Column names are in order as presented on the
heat map in Figure 1B with the first column name representing the left
most column.
Additional file 5: Figure S1. Percent error of the model between
measured and predicted survival values across different variables. A) The
absolute percent difference between the measured and predicted
survival values for each treatment. The error for the docetaxel treatmentgroup is significantly different from all other treatment groups (*** equals
a P-value < 0.001). B) The absolute percent difference between the
measured and predicted survival values grouped by inhibitor treatment on
LNCaP cells. C) The absolute percent difference between the measured and
predicted survival values as grouped by cell line.
Additional file 6: Figure S2. Survival of PC3, LNCaP, and MDA-PCa-2b
cells in androgen depleted media. Cell survival in androgen depleted
conditions as compared to the normal growth media condition as
measured with an MTT assay. One hundred percent is equal to the
mean of that cell line in culture with its normal growth media. All pairs
of groups were significant from each other at the 95% confidence
interval (*** equals P-values < 0.001.
Additional file 7: Figure S3. The measured versus predicted survival of
LNCaP cells. The predicted versus measured survival of LNCaP cells treated
with targeted kinase inhibitors in combination with ligand treatments and
docetaxel. A R2 value of 0.58 was calculated based on the partial least
squares regression performed.
Additional file 8: Figure S4. The weights of the regression coefficients
from PLSR for each cell line calculated individually. The regression
coefficient’s weights for three different partial least squares regression
models constructed on the data for the LNCaP, PC3, or MDA-PCa-2b cell
lines when treated with EGF, IGF1, IL6, TNFα, DHT, and docetaxel.
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